New mineralocorticoid receptor antagonists: update on their use in chronic kidney disease and heart failure

Chronic hyperkalemia in non-dialysis CKD: controversial issues in nephrology practice

(2018) Luca De Nicola et al.   JOURNAL OF NEPHROLOGY

The myeloid mineralocorticoid receptor controls inflammatory and fibrotic responses after renal injury via macrophage interleukin-4 receptor signaling

(2018) Jonatan Barrera-Chimal et al.   KIDNEY INTERNATIONAL

New Sides of Aldosterone Action in Cardiovascular System as Potential Targets for Therapeutic Intervention

(2018) Patrycjusz Kolodziejczyk et al.   CURRENT DRUG TARGETS

Aldosterone Target NGAL (Neutrophil Gelatinase–Associated Lipocalin) Is Involved in Cardiac Remodeling After Myocardial Infarction Through NFκB PathwayNovelty and Significance

(2017) Ernesto Martínez-Martínez et al.   HYPERTENSION

Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Protects Against Acute Kidney Injury–Mediated Chronic Kidney DiseaseNovelty and Significance

(2017) Lionel Lattenist et al.   HYPERTENSION

30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development

(2017) Peter Kolkhof et al.   JOURNAL OF ENDOCRINOLOGY

Benefit of Mineralocorticoid Receptor Antagonism in AKI: Role of Vascular Smooth Muscle Rac1

(2017) Jonatan Barrera-Chimal et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Renin–angiotensin system blockade: Finerenone

(2017) Luis M. Ruilope et al.   Nephrologie & Therapeutique

The novel mineralocorticoid receptor antagonist finerenone attenuates neointima formation after vascular injury

(2017) Jochen Dutzmann et al.   PLoS One

Mineralocorticoid Receptor Signaling as a Therapeutic Target for Renal and Cardiac Fibrosis

(2017) Greg H. Tesch et al.   Frontiers in Pharmacology

Mineralocorticoid Receptor Antagonists in End-Stage Renal Disease: Efficacy and Safety

(2016) Andrew S. Bomback   BLOOD PURIFICATION

Cardiac Tissue Injury and Remodeling Is Dependent Upon MR Regulation of Activation Pathways in Cardiac Tissue Macrophages

(2016) Jimmy Z. Shen et al.   ENDOCRINOLOGY

A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease

(2016) Gerasimos Filippatos et al.   EUROPEAN HEART JOURNAL

Low glomerular filtration rate and risk of myocardial infarction: A systematic review and meta-analysis

(2016) Vishal Vashistha et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Steroidal and Nonsteroidal Mineralocorticoid Receptor Antagonists Cause Differential Cardiac Gene Expression in Pressure Overload-induced Cardiac Hypertrophy

(2016) Jana Grune et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY

Controversial issues in CKD clinical practice: position statement of the CKD-treatment working group of the Italian Society of Nephrology

(2016) Vincenzo Bellizzi et al.   JOURNAL OF NEPHROLOGY

Pharmacokinetics, distribution, and disposition of esaxerenone, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist, in rats and monkeys

(2016) Makiko Yamada et al.   XENOBIOTICA

Hyperkalemia constitutes a constraint for implementing renin-angiotensin-aldosterone inhibition: the widening gap between mandated treatment guidelines and the real-world clinical arena

(2016) Murray Epstein   Kidney International Supplements

Relation of Aortic Valve Calcium to Chronic Kidney Disease (from the Chronic Renal Insufficiency Cohort Study)

(2015) Marie A. Guerraty et al.   AMERICAN JOURNAL OF CARDIOLOGY

Underprescription of Renin–Angiotensin System Blockers in Moderate to Severe Chronic Kidney Disease

(2015) Shayan Shirazian et al.   AMERICAN JOURNAL OF THE MEDICAL SCIENCES

Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist

(2015) Kiyoshi Arai et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

CS-3150, a novel non-steroidal mineralocorticoid receptor antagonist, prevents hypertension and cardiorenal injury in Dahl salt-sensitive hypertensive rats

(2015) Kiyoshi Arai et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Rac1-Mediated Activation of Mineralocorticoid Receptor in Pressure Overload–Induced Cardiac InjuryNovelty and Significance

(2015) Nobuhiro Ayuzawa et al.   HYPERTENSION

Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy

(2015) George L. Bakris et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Finerenone Impedes Aldosterone-dependent Nuclear Import of the Mineralocorticoid Receptor and Prevents Genomic Recruitment of Steroid Receptor Coactivator-1

(2015) Larbi Amazit et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Aldosterone-induced expression of ENaC-α is associated with activity of p65/p50 in renal epithelial cells

(2015) Rongquan Chen et al.   JOURNAL OF NEPHROLOGY

Intersection of cardiovascular disease and kidney disease

(2014) Nisha Bansal et al.   CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION

Emerging drugs for chronic kidney disease

(2014) Sergio Stefoni et al.   EXPERT OPINION ON EMERGING DRUGS

Finerenone, a Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Protects From Rat Cardiorenal Injury

(2014) Peter Kolkhof et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY

Aldosterone synthase inhibitors in cardiovascular and renal diseases

(2014) P. Namsolleck et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: An emerging paradigm in diabetic nephropathy

(2013) Thomas A. Mavrakanas et al.   European Journal of Internal Medicine

Incidence and Predictors of Postoperative Atrial Fibrillation in Kidney Transplant Recipients

(2013) Gaetano La Manna et al.   TRANSPLANTATION

ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012

(2012) et al.   EUROPEAN JOURNAL OF HEART FAILURE

Oxidative Stress Causes Mineralocorticoid Receptor Activation in Rat Cardiomyocytes

(2012) Miki Nagase et al.   HYPERTENSION

Aldosterone blockade and the mineralocorticoid receptor in the management of chronic kidney disease: current concepts and emerging treatment paradigms

(2012) Linda Shavit et al.   KIDNEY INTERNATIONAL

Aldosterone and cardiovascular disease: the heart of the matter

(2012) B. Julie He et al.   TRENDS IN ENDOCRINOLOGY AND METABOLISM

Deletion of Cardiomyocyte Mineralocorticoid Receptor Ameliorates Adverse Remodeling After Myocardial Infarction

(2011) Daniela Fraccarollo et al.   CIRCULATION

Effect of eplerenone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric chronic hemodialysis patients – a pilot study

(2011) L. Shavit et al.   CLINICAL NEPHROLOGY

Minireview: Aldosterone and Mineralocorticoid Receptors: Past, Present, and Future

(2010) John W. Funder   ENDOCRINOLOGY

Aldosterone and Mineralocorticoid Receptors in the Cardiovascular System

(2010) John W. Funder   PROGRESS IN CARDIOVASCULAR DISEASES

Use of Aldosterone Antagonists in Heart Failure

(2009) Nancy M. Albert   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Corticosteroid receptors, macrophages and cardiovascular disease

(2009) Amanda J Rickard et al.   JOURNAL OF MOLECULAR ENDOCRINOLOGY

Addition of Angiotensin Receptor Blockade or Mineralocorticoid Antagonism to Maximal Angiotensin-Converting Enzyme Inhibition in Diabetic Nephropathy

(2009) U. F. Mehdi et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Change in Proteinuria After Adding Aldosterone Blockers to ACE Inhibitors or Angiotensin Receptor Blockers in CKD: A Systematic Review

(2008) Andrew S. Bomback et al.   AMERICAN JOURNAL OF KIDNEY DISEASES